Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

INTRODUCTION: Ertugliflozin is an oral sodium-glucose cotransporter 2 inhibitor that is being developed to treat type 2 diabetes mellitus (T2DM). This study assessed the efficacy and safety of co-initiation of ertugliflozin and sitagliptin compared with placebo in patients with T2DM inadequately con...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Sam, Krumins, Tania, Zhou, Haojin, Huyck, Susan, Johnson, Jeremy, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801244/
https://www.ncbi.nlm.nih.gov/pubmed/29313282
http://dx.doi.org/10.1007/s13300-017-0358-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801244/
https://www.ncbi.nlm.nih.gov/pubmed/29313282
http://dx.doi.org/10.1007/s13300-017-0358-0

Ejemplares similares